Humanigen to Present at J.P. Morgan Healthcare Conference
(Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ˜cytokine storm with its lead drug candidate, lenzilumab„¢, today announced that the Companys management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021. Cameron Durrant, MD, MBA, chief executive officer of Humanigen, Dale Chappell, MD, MBA, chief scientific officer, and Timothy Morris, chief operating and financial officer, will provide an update on enrollment for its Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19, an update on the commercial preparation ahead of a potential Emergency Use Authorization (EUA) for lenzilumab as well as an overview of the Companys other programs.
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME, Calif. (Business Wire) Humanigen, Inc.
(NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases,
today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is supported by funding from the Cure Brain Cancer Foundation. Results from the study, being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia, are expected in the first half of 2021.
Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update
th, 2020 and provided a business update.
Pankaj Mohan, Ph.D., Founder and CEO commented, This year has been incredibly exciting for Sonnet. We successfully executed our public listing, generated compelling new data to support our therapeutic pipeline and are working to finalize our first out-licensing deal. We believe this positions us well for continued growth and our IND submissions in 2021.
Fiscal Year 2020 and Recent Corporate Updates
Warrant Repricing and Exchange: On August 4
th, Sonnet announced a warrant repricing and exchange that provided the company with approximately $10.5 million of gross proceeds. This restructuring simplified the Company s capital structure and significantly reduced potential future dilution, while providing capital for ongoing operations.